Study of Pelabresib for advanced cancer with liver issues
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests how the drug pelabresib works in people with advanced cancer who also have mild to severe liver problems. It aims to understand safety and how the drug moves through the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have advanced cancer that no longer responds to standard treatments.
- You have certain liver function levels (normal or moderately to severely impaired) as measured by blood tests.
- Your blood counts (platelets, neutrophils) and kidney function are within acceptable ranges.
- You have not had major surgery, chemotherapy, or radiation recently without full recovery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how a new drug (pelabresib) interacts with other medicines like diabetes pills, a sedative, and birth control pills. It is for people with advanced cancer to help understand safe dosing.
This is a follow-up study for people who are already taking the drug pelabresib in another trial and are doing well on it. It allows you to continue receiving pelabresib and monitors your health over a longer period.
This trial tests a combination of two drugs (pelabresib and ruxolitinib) for people with myelofibrosis whose spleen is enlarged and who have bothersome symptoms. It aims to see if adding pelabresib to standard care helps control the disease better.
This study tests adding a new drug (pelabresib) to the standard treatment (ruxolitinib) for Japanese people with myelofibrosis. The goal is to see if the combination helps control symptoms like an enlarged spleen.
This trial tests a drug called palbociclib for people with advanced liver cancer who have already tried at least two other treatments. The goal is to see if palbociclib can help shrink the cancer or slow its growth.
This early-phase study tests how safe ABSK-011 is, what side effects it causes, and how the body processes the drug. It may help certain patients with advanced solid cancers (including some liver cancer cases) whose tumors have specific test results.
Hear when a new Advanced Malignancies and Hepatic Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.